This is not the same GLP-1 market people were comparing in late 2025. More enforcement attention, settlement pressure, and lower-price oral options changed which providers still look credible.
What I Looked At
Before ranking anything, here is the short list of criteria this article weighs:
- Pharmacy identity and certifications (named facility, 503A status, USP-797 compliance, LegitScript)
- Lot tracking and quality controls (bench-to-door traceability, published purity testing)
- Shipping speed and geographic reach (overnight vs. standard, states covered)
- Physician oversight model (how fast, how qualified, how much ongoing monitoring)
- Transparent pricing (cash price, no hidden enrollment fees)
No single provider is perfect on all five. Here is how the field shakes out.
The Ranked List
1. HealthRX
This is the pick for the cash-pay patient who wants a named, verifiable pharmacy at a genuinely low price point with overnight shipping. HealthRX dispenses compounded semaglutide starting at $99 per month and compounded tirzepatide from $149 per month. Both are once-weekly injections. Free overnight shipping goes to all 50 states with no hidden fees attached.
The pharmacy detail is what sets it apart from most of the field. Medication is dispensed by Manifest Pharmacy in Greer, South Carolina, a 503A compounding facility operating under USP-797 standards with lot-level tracking from production to delivery. That is a specific, checkable fact, not a vague reference to “our pharmacy partner.” Manifest also holds LegitScript certification (certificate 50087439), which is an independent verification layer that many compounders skip. A US board-certified physician reviews each patient assessment within roughly 24 hours.
One honest caveat: these are compounded medications, not FDA-approved drugs, and HealthRX does not claim equivalency to branded injectables like Wegovy or Mounjaro.
2. FormBlends
FormBlends occupies a specific niche. It publishes per-product purity testing results, including HPLC purity percentages, mass spectrometry identity confirmation, and endotoxin sterility data, directly alongside its product listings. Very few GLP-1 telehealth brands do this at all. Medication ships from an FDA-registered 503A compounding pharmacy, and physician oversight is part of the model throughout.
Pricing is higher than HealthRX. Semaglutide runs around $299 per vial and tirzepatide around $349. Shipping covers 47 states, not all 50. Why does it rank here despite the higher cost? Because for a patient who specifically wants documented batch-level chemistry before injecting anything, FormBlends offers something the rest of this list does not. It also carries a wide peptide catalog covering recovery, longevity, and cognitive peptides under the same clinician model, which makes it worth knowing about if GLP-1s are one part of a broader protocol rather than the whole picture.
3. Mochi Health
Mochi Health requires board-certified obesity-medicine physicians, not general practitioners, to manage its patients. That is not typical for telehealth. Compounded semaglutide starts around $99 per month and tirzepatide around $199, which puts the pricing in a competitive range. Monitoring is more hands-on than some cash-pay alternatives. The tradeoff is that the pharmacy infrastructure is less publicly documented than HealthRX or FormBlends, so patients who want to verify facility details will need to ask directly.
4. Hims & Hers
Hims & Hers shifted entirely away from compounded GLP-1s after the March 2026 Novo Nordisk settlement, so it now sells branded medications only. Wegovy runs approximately $299 per month through the platform, oral options around $249, and Zepbound around $399. With insurance plus a savings card, costs can drop to $0 to $25. That is a genuinely compelling path for insured patients. The pharmacy standards here default to the brand manufacturers’ own facilities, which removes the compounding question entirely. The limitation is that cash-pay patients without strong insurance will find the prices steep.
5. Ro Body
Ro has a dedicated prior-authorization team that works to get branded GLP-1s covered through insurance, which is a real operational service that most competitors do not replicate internally. Membership starts around $39 for the first month, then $74 to $149 monthly, with medication billed separately. Ro also accepts insurance for branded medications. The platform is well-structured for patients who want clinical support alongside their prescription. Pharmacy oversight follows branded-drug standards, which sidesteps the compounding compliance question entirely.
How to Choose
Decide your priorities before picking a provider. If cash price and overnight shipping to any state matter most, HealthRX is the clearest answer at this price tier. If you want published purity testing or access to a broader peptide catalog beyond GLP-1s, FormBlends is worth the higher per-vial cost. If you have good insurance, Hims & Hers or Ro can make branded medications genuinely affordable. And if you want obesity-specialist physicians managing your care directly, Mochi Health is the outlier that takes that piece seriously.
Compounded medications in any form carry risks that branded, FDA-approved options do not. Talk to a physician who knows your full medical history before starting any GLP-1 program, regardless of which platform you use.
Common Questions
What does 503A status actually mean for a compounding pharmacy supplying GLP-1s?
A 503A designation means the pharmacy compounds medications on a per-patient, prescription-by-prescription basis under state board oversight rather than in large batches for general distribution. It does not equal FDA approval of the drug itself. For GLP-1 patients, it means the facility is operating within a defined legal framework, but you should still verify USP-797 compliance and independent certifications like LegitScript separately.
Why does HealthRX name its pharmacy while most telehealth platforms do not?
Most platforms treat their compounding partner as a vendor relationship they prefer not to publicize, partly for competitive reasons and partly because naming a facility invites direct scrutiny. HealthRX naming Manifest Pharmacy in Greer, South Carolina, with a specific LegitScript certificate number, is genuinely unusual. It gives patients a verifiable third-party record to check rather than a marketing claim to take on faith.
Is FormBlends’ published purity testing actually meaningful, or is it a marketing tactic?
Publishing HPLC purity percentages, mass spectrometry identity results, and endotoxin data per batch is meaningful if the testing is done by an independent laboratory rather than in-house. Patients should ask whether the certificates of analysis come from a third-party lab. If they do, that documentation is a real quality signal. If the testing is self-reported, it carries less independent weight.
After Hims & Hers stopped compounding, does the pharmacy standards question still apply to their GLP-1 offerings?
No, not in the same way. Once a platform switches to branded medications like Wegovy or Zepbound, the manufacturing standards are set by Novo Nordisk and Eli Lilly respectively, both operating under full FDA approval. The compounding compliance question disappears. What remains relevant for Hims & Hers patients is insurance coverage and whether the platform’s physician oversight matches what a traditional prescriber would provide.
Can a patient switch between these providers mid-treatment without starting the titration schedule over?
Practically, yes, though it depends on timing and the receiving platform’s intake process. Most telehealth providers will ask for your current dose and recent injection date during onboarding and can continue from where you are. The bigger friction point is prescription transfer, since compounded medications cannot be transferred between pharmacies the way a standard retail prescription can. Expect a new physician review and a short delay when switching.
Sources
- FDA warning letters to telehealth and compounding firms, early 2026 (FDA.gov enforcement records)
- SURMOUNT-1 trial (tirzepatide, NEJM, 2022): approximately 21% body weight reduction at 72 weeks
- STEP 1 trial (semaglutide, NEJM, 2021): approximately 15% body weight reduction at 68 weeks
- Novo Nordisk settlement announcement, March 9, 2026 (public press release)
- LegitScript compounding pharmacy certification database (LegitScript.com)
- USP-797 pharmaceutical compounding standards (USP.org)
